Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
22.75
+0.12 (0.53%)
At close: Jan 21, 2026, 4:00 PM EST
22.30
-0.45 (-1.98%)
After-hours: Jan 21, 2026, 7:41 PM EST
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,294 employees as of December 31, 2024. The number of employees increased by 18 or 1.41% compared to the previous year.
Employees
1,294
Change (1Y)
18
Growth (1Y)
1.41%
Revenue / Employee
$487,325
Profits / Employee
-$448,090
Market Cap
2.19B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,294 | 18 | 1.41% |
| Dec 31, 2023 | 1,276 | -35 | -2.67% |
| Dec 31, 2022 | 1,311 | 192 | 17.16% |
| Dec 31, 2021 | 1,119 | 226 | 25.31% |
| Dec 31, 2020 | 893 | 153 | 20.68% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Sarepta Therapeutics | 1,372 |
| Recursion Pharmaceuticals | 800 |
| Galapagos NV | 704 |
| Harmony Biosciences Holdings | 268 |
| Nuvation Bio | 220 |
| Soleno Therapeutics | 152 |
| Maze Therapeutics | 125 |
RARE News
- 9 days ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 9 days ago - Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference - GlobeNewsWire
- 22 days ago - Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewsWire
- 22 days ago - Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm - GlobeNewsWire
- 22 days ago - Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain - Benzinga
- 23 days ago - These biotech stocks are getting hammered by shocking brittle-bone treatment study results - Market Watch
- 23 days ago - Ultragenyx's bone disease drug fails late-stage trials - Reuters
- 23 days ago - Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta - GlobeNewsWire